LEXINGTON, Mass. - (Business Wire) TARIS Biomedical, a specialty pharmaceutical company pioneering the field of drug-device convergence for targeted therapies, launched today and announced it has secured $15 million in Series A financing. Leading venture capital firms Flagship Ventures, Flybridge Capital Partners and Polaris Venture Partners co-led the investment in TARIS, which was founded by internationally renowned scientists from the Massachusetts Institute of Technology (MIT), Michael Cima, Ph.D.

Expands VisEn’s Leading Fluorescence Molecular Imaging Agent Portfolio to Enable Breakthrough Readouts of Cathepsin-K Biomarkers in Research and Drug Development

Humana health-plan members in Chicago and South Florida volunteered to participate in study

Single molecule sequencing provides first amplification-free, unbiased view of a transcriptome

Funds Will Provide Additional Working Capital to Support Strong Market Demand for Accuri C6 Flow Cytometer® System and Accuri CSampler™

Two years into development, innovative startup enables path to energy independence; Unveils proprietary production system capable of supplying unlimited quantities of renewable fuel at costs competitive with fossil fuels

BEDFORD, MA (July 30, 2009)-- VisEn Medical Inc., a leader in fluorescence in vivo imaging from research through medicine, announced today that scientists reporting in the July 31 issue of SCIENCE have discovered a key disease-related biologic pathway using an integrated and innovative array of in vitro readouts and advanced in vivo imaging technologies. The newly reported biologic pathway relates to monocyte deployment from the spleen to inflammatory sites, including myocardial infarction.

WILMINGTON, Mass. and STAMFORD, Conn. – August 4, 2009 – Advanced Electron Beams (AEB), whose compact electron beam technology helps traditional manufacturers become more environmentally sustainable while improving profitability, and GE Energy Financial Services, a unit of GE (NYSE: GE) announced today the close of a $14.2 million Series C financing, bringing AEB’s total amount raised to more than $50 million since October 2005.

Study Performed at Stanford University Published in Nature Biotechnology

Research team led by Dr. Daniel Haber to explore applicability of Helicos's technology to the molecular characterization of circulating tumor cells

CAMBRIDGE, Mass., Aug 13, 2009 (BUSINESS WIRE) -- Helicos BioSciences Corporation (NASDAQ: HLCS), a life science company focused on innovative genetic analysis technologies, today announced the placement of a Helicos(TM) Genetic Analysis System at the Massachusetts General Hospital (MGH) Cancer Center in the laboratory of Daniel Haber, MD, PhD.